• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Is active targeting of brain metastases of breast cancer superior to passive targeting?

    2019-07-30 03:16:56NermeenKamaIFatemaEIAmrawyHebaAbduIIahAIiIvanEdafioghoMohamedIsmaiINounou

    Nermeen H. KamaI*, Fatema EI-Amrawy*, Heba AbduIIah AIi, Ivan Edafiogho, Mohamed IsmaiI Nounou

    1Department of Pharmaceutics, College of pharmacy, Arab Academy for Science, Technology and Maritime Transport(AASTMT), Alexandria 1029, Egypt.

    2Biomedical Informatics and Medical Statistics Department, Medical Research Institute (MRI), Alexandria University, Alexandria 21561, Egypt.

    3Department of Pharmaceutics and Industrial Pharmacy, College of Pharmacy for Girls, Al Azhar University, Cairo 11651, Egypt.

    4Department of Pharmaceutical Sciences (DPS), School of Pharmacy and Physician Assistant Studies (SOPPAS), University of Saint Joseph (USJ), Hartford, CT 06103, USA.

    *Both authors contributed equally to the manuscript and are both considered first authors.

    Abstract Brain metastasis is a major cause of death in patients with solid cancers. Breast cancer cells have high tendency to migrate towards brain. Cancer cells within brain are characterized by severe aggressiveness and inaccessibility.Currently, breast cancer and its metastasis are the second leading cause of death among women. Tumor microenvironment and blood brain barrier (BBB) represent great obstacles in targeting breast cancer and its metastasis. Chemotherapy is a safer treatment modality for brain metastasis compared with risky surgical resection and brain radiotherapy. Unfortunately, conventional chemotherapy lack penetration of BBB and suffer from multiple resistance mechanisms. Current treatment technologies for brain metastases of breast cancer have limited long-term success and numerous side effects, illustrating the urgent need for novel smart strategies.Various novel drug entities and nanosystems have been employed to improve diagnosis and targeted treatment of breast cancer and its metastasis. Immunotherapy agents and small tyrosine kinase inhibitors have been shown to reduce tumor size and increase survival in patients with breast cancer, but still poorly penetrate BBB. Tailored sized nanoparticles to some extent crossed brain tumor barrier and enhanced drug accumulation in tumors by taking advantage of enhanced permeability and retention. Furthermore, various active targeting strategies have been adopted to improve accessibility to brain malignancies. Therefore, to achieve enhanced antitumor therapy against breast cancer and its brain metastasis, multi-talented delivery systems are urgently needed for optimal treatment.This review focuses on the various active and passive targeting technologies for the treatment of breast cancer brain metastases in the past decade. A comprehensive summary and examples along with pros and cons of each system will be discussed. Different treatment modalities and nanotechnology facilities will be demonstrated to aid in designing the optimal smart, safe, targeted and effective systems to combat brain metastases of breast cancer.

    Keywords: Active targeting, passive targeting, brain metastasis, breast cancer

    INTRODUCTION

    Despite the recent pharmaceutical and medical advances in treatment and diagnosis of different carcinogenic tissues and their metastases, brain and central nervous system (CNS) primary and metastatic tumors remain a tough hurdle to overcome due to physiological and anatomical barriers represented by blood brain barrier(BBB) and the aggressiveness and continuous adaptive evaluation of this tumor tissue.

    As systemic therapy of metastatic breast cancer advances, survival rates of patients are enhanced. On the other side, the incidence of brain and CNS complications increases[1]. In historical series, the risk of developing brain metastasis has been estimated among women with stage IV breast cancer to range from 10% to 16% among living making it the second most common cause of metastatic brain tumor after lung cancer (10%-25%)[2-4]. The development of breast cancer brain metastases (BCBM) tends to vary by the subtype. Forty-six percent of patients with advanced triple negative breast cancer, and up to thirty-seven percent of patients with HER2-positive breast cancer relapse due to intracranial metastases, despite control of the peripheral tumors[5-8].

    Treatment options are limited and usually involve multimodality approaches that include surgery,radiotherapy, radiosurgery, and rarely systemic therapy, depending on the number of CNS lesions[9,10]. The unpredictable extent of therapeutics that can reach tumor vasculature of BCBM has been the challenge in developing effective treatments for these patients[11,12]. BBB has always been a challenge to drug delivery to brain tissues[13-16]. However, during brain metastases, the structure and integrity are altered forming a“Blood Brain Tumor Barrier” (BBTB)[17]. The leaky structure of BBTB is an appealing strategy to target brain tumors[18]. Approaches to deliver drugs into the brain are being extensively studied [Figure 1].

    Beside the common technologies including viral vectors and nanoparticles, novel non-invasive techniques such as ultrasound alteration and magnetic stimulation have been studied to temporally open the BBB to enhance brain drug uptake. In this review, we discuss passive and active targeting BCBMs.

    BBB AND DRUG DELIVERY

    The BBB, as a morphologic and physiologic barrier, protects the brain tissue from the peripheral vasculature,protecting normal brain function by impeding most compounds from transiting from the blood to the brain[13,16,18]. There is a common misconception about the nature of BBB as a protective barrier or sac protecting the brain underneath it. Perhaps, the term BBB was the main reason of such misconception.The BBB is mainly a fortified special vascular structure in the brain different from the common vascular structure in the rest of the body. Mainly, the brain capillary endothelial cells (BCECs) form the BBB, besides other cell types such as pericytes, astrocytes, and neuronal cells; playing an important role in the function of the BBB[19]. BCEC have tight junctions that prevent paracellular transport of small and large (water soluble) compounds from the circulation to the brain except for some very small or gaseous molecules, such as water and carbon dioxide[17,19,20]. The components of the BBB continuously adapt in response to various physiological changes in the brain[21][Figure 1].

    Similarly, BCECs restrict drug distribution into the brain by limiting drug diffusion from blood to brain.In addition to these physical barriers, cells, like pericytes, and astrocyte foot processes, express several drug metabolizing enzymes that inactivate drugs reducing the distribution of active drugs to the brain. Thus,complicating barrier mechanisms & the presence of both drug-uptake and drug efflux mechanisms such as multidrug transporters including P-glycoprotein (ABCB1/MDR1) and ABCG2. Some compounds pass the BBB by passive non-saturable diffusion, some by active transport; others are actively excluded, and still,others enter through endocytosis[12].

    Figure 1. The vascular and structural components of the blood brain barrier (BBB) and the blood brain tumor barrier

    BRAIN METASTASES OF BREAST CANCER

    The occurrence of brain metastases depends on how breast cancer cells adapt to and survive in foreign environments[22]. Specific homing molecules mediate organ-specific metastasis formation on the heterogeneous tumor cell surface[23]. Investigating throughout the metastatic cascade is one area of research that can lead to the development of effective treatment.

    Research has shown that at the time of initial diagnosis of primary cancer, circulating tumor cells can be found in the bloodstream of patients[24]. Breast cancer stem cells are characterized by the ability to self-renew along with their high level of resistance to radiation and chemotherapeutic agents[25]. After detachment of tumor cells from the primary lesion, invasion into the CNS and bypassing the BBB occur, followed by sustained proliferation towards the formation of brain metastases[26,27]. Studies have suggested that brain metastases originate from cells as a primary mass or lymph nodes or from other visceral metastases[28].

    Disruption of the BBB was shown to involve mediators of extravasation through non-fenestrated capillaries.A number of mediators have been identified to assist breast cancer cells crossing the BBB, including cyclooxygenase-2, heparin-binding epidermal growth factor-like growth factor, and the α2, 6-sialyltransferase ST6GALNAC5[29-34].

    The recently identified extracellular (circulating or exosomal) miRNAs were shown to mediate the ability of metastatic breast cancer cells to target the distant brain endothelium and vasculature[35]. The metastatic BC cells in brain express high levels of anti-plasminogen activator serpins as a shield to escape from the reaction of brain stroma, conferring the adherence of infiltrating breast cancer cells to the surface of capillaries and the growth on the vasculature[36].

    Brain metastases of breast cancer are also subject to the limited permeability characteristics of the BBB in-spite of the formation of the BBTB with altered integrity. MRI data have shown that not all brain metastases display elevated BBTB permeability[37]. The changes in BBTB vascular permeability are usually not homogenous throughout the lesion[38,39]. It was noticed that brain metastases from HER2+ breast cancers infiltrate brain tissue crossing the endothelial cells without disrupting the BBB, unlike the brain metastases from triple negative or basal-type breast cancers that often disrupt the BBB[8,40][Figure 1].

    Figure 2. Different adopted strategies for actively and passively targeting brain metastases of breast cancer to overcome the blood brain barrier (BBB) hurdles

    TARGETING BRAIN METASTASES

    Although, there are no FDA-approved systemic treatments for BCBM to date[41], patents and studies in the past years have shown promising progress and well-established techniques to overcome the BBB/BBTB[42]. There are two general strategies adopted to facilitate crossing the BBB; invasive and non-invasive techniques[43]. The invasive techniques rely primarily on disrupting the BBB integrity by direct intracranial drug delivery through intracerebroventricular, intracerebral or intrathecal administration, osmotic pumps or biochemical means[43]. But all these approaches are severely limited by poor distribution into brain parenchyma[44]. On the other hand, non-invasive methods include drug moieties modifications through the transformation of the drug into lipophilic analogs, prodrugs, chemical drug delivery, carrier-mediated drug delivery, receptor/vector-mediated drug delivery and intranasal drug delivery[43,45].

    Diffusion of substances into the brain can be divided into paracellular and transcellular. Generally, BBB targeting strategies can be categorized into passive (transcellular lipophilic pathway) and active targeting(mainly; transcytosis)[46]. Figure 2 summarizes the targeting techniques covered in this article.

    Passive targeting

    Enhanced permeability and retention phenomenon

    Passive targeting depends mainly on the preferential accumulation of drug molecules into tumor cells[47].Enhanced permeability and retention (EPR) phenomenon based on the nanometer size range of the nanoparticles and two fundamental characteristics of the neoplastic tissues, namely, the leaky vasculature and impaired lymphatic drainage. EPR was first described by Maeda and Matsumura[48]. The selective high local concentration of nanosized anticancer drugs in tumor tissues enhances the therapeutic effect with minimal side effects in both preclinical and clinical settings[49].

    Various important factors such as circulation time, targeting and the capability to overcome BBB are heavily reliant on the shape, size and the surface area of these particles. In passive diffusion, lipid solubility,molecular weight, and the presence of tight junctions greatly affect the degree of permeation[50,51].

    Conventionally, a particle must be at least 10 nm in diameter to avoid clearance by first-pass renal filtration and the optimal size range of 100-180 nm will ensure longer circulation time, increased accumulation within the tumor mass and lower renal clearance[52,53]. Moreover, surface characteristics also play a very important role in determining the extent of internalization of these nanoparticles into cells. Relatively, the surface can be modified by the polymer composition, thus governing an extra amount of hydrophobicity or hydrophilicity to these particles[51]. Supplementary Table 1 illustrates some of the papers using passive targeting technology in targeting BCBM.

    Nanotechnology as a tool for targeting EPR

    Nanotechnology paved the road towards safer and more likely effective cancer treatment strategies that can overcome some of the hurdles for drug delivery. Nano-medicines primarily aim to improve the circulation time of the conjugated or entrapped (chemo-) therapeutic drugs[54]. Examples of nanoparticles commonly used include: polymeric particles, polymeric micelles, dendrimers, and liposomes. Nanoparticles represent versatile tools to encapsulate various types of drugs, either hydrophilic or hydrophobic moieties altering their physicochemical parameters and pharmacokinetics profile[55].

    Beside increasing drug-site contact time, some polymers used in nanoparticles formulations such as polylactic-co-glycolic acid (PLGA) have high cell adhesion property, increasing the drug concentration gradient at the adhesion site by longer drug carrier contact time with the targeted cells[56].

    However, nanoparticles can show some serious adverse effects[57]. Adverse effects of nanoparticles depend on individual factors such as genetics, existing disease conditions, exposure, nanoparticle chemistry, size,shape, agglomeration state, and electromagnetic properties[57]. The key to understanding the toxicity of nanoparticles is their size; nanoparticles are smaller than cells and cellular organelles, which allow them to penetrate these biological structures, disrupting their normal function[57]. Examples of toxic effects include tissue inflammation, and altered cellular redox balance toward oxidation, causing abnormal function or cell death[57]. Furthermore, a major drawback is the difficulty in scaling up the formulation and its transformation to clinical use, due to high cost and instability during storage. The NP materials must be biocompatible and safe when administered[58].

    Lipsomes

    Liposomal (Liposome: lipid vesicle in Latin) nanocarrier systems are vesicular lipid bilayer colloidal spheres formed by self-assembly[59]. Without the use of surface modification by a hydrophilic polymer such as polyethylene glycol (PEG), the biological half-lives of liposomes are very short due to several factors including the tendency of the liposome to exchange lipid materials with cell membranes and their uptake by phagocytes. Mohammadet al.[60]noticed increased survival rates in animals treated with liposomal irinotecan (nal-IRI) that sustained the accumulation of irinotecan and its active metabolite in the brain metastases lesions, unlike non-liposomal irinotecan whose distribution in the CNS was hampered by BBTB and various efflux proteins. The size of nal-IRI was between 100-110 nm, which enhanced its preferential accumulation within tumor due to EPR through the leaky vasculature of the tumor[60]. Drawbacks of liposomes involved their rapid uptake by the Reticulo-Endothelial System (RES) and consequent removal from circulating blood.

    PEGylation

    The main pharmacokinetic outcomes of PEGylation include: changes occurring in overall circulation lifespan, tissue distribution pattern, and elimination pathway of the parent drug/particle[61]. PEG mainly protects these particles from being phagocytosed by natural particle eliminating mechanisms, mainly organs of the RES[62].

    Pegylated nanoparticles are characterized by hydrophilic surfaces that circumvent opsonization and decrease their clearance by macrophage, which results in prolonged circulation[51]. PEGylation has been shown to alter the pharmacokinetics of doxorubicin considerably; the total clearance was significantly reduced[63]. In the early 1990’s, PEGylated polymeric vesicles were introduced by Yokoyamaet al.[64], which represented an important milestone in the synthesis of long-circulating liposomal formulations (STEALTH? liposomes).Liposomal formulations are the first novel controllable carrier systems to be sold in the market for cancer(Doxil?, PEGylated liposomal formulation encapsulating doxorubicin(PLD)[65-67]. PLD showed reduced cardiotoxicity and prolonged activity.

    Anderset al.[68]encapsulated doxorubicin in pegylated liposomes (PLD) that achieved 20 folds higher concentration of doxorubicin within intracranial tumors compared to non-liposomal doxorubicin, whose distribution was compromised by BBTB. Moreover, co-administration of PLD and BBB permeable ABT-888, an inhibitor of a poly (ADP-ribose) polymerase, showed better survival as compared to non-liposomal doxorubicin and ABT-888.

    NektarTMTherapeutics has several patents on PEGylation bioconjugation aiming to modify the pharmacokinetic profile[69-75]. Adkinset al.[76]formulated NKTR-102, an Irinotecan-PEG conjugate linked with a hydrolysable ester bond, whose polymer moiety resulted in prolonged circulation and subsequently increased tumor localization. The innovative nature of this PEGylated system is the adoption of the threedimensional (3D) branching technology in the PEGylation to provide superior pharmacokinetics and pharmacokinetic parameters. The 3D propriety Nektar PEG technology offers weeks of half-lives compared to days in conventional PEG[76]. The preferential accumulation of NKTR-102 within brain metastases via EPR, its reduced clearance and ability to escape P-glycoprotein mediated efflux resulted in continuous release of the active metabolite SN38 and better therapeutic efficacy.

    NektarTMTherapeutics is not the only pharmaceutical company relying on innovative PEGylation technologies for passively targeting brain metastases of breast cancer. Other companies, such as 2-BBB,is investing heavily on the use of PEGylation bioconjugated with liposomal vesicular carrier systems to passively target brain metastases of breast cancer[77]. BBB adopts a propriety G-Technology? for targeting the brain. 2-BBB’s G-Technology? empowers sustained delivery of systemically administered therapeutics to the brain with high safety and efficacy profiles. The G-Technology? uses PEG and glutathione bioconjugated to active pharmaceutical ingredients loaded liposomal vesicular structures. Polyethylene glycol (PEG) is attached to the liposomes to provide a prolonged circulation time in the blood stream with sustained halflife pharmacokinetic profile. Glutathione is bioconjugated to the PEG molecules to offer targeted safe and effective delivery of the therapeutics across the BBB[78].

    2-BBB has adopted its G-Technology? in developing two lead clinical programs targeting multiple indications of brain cancers and neuroinflammatory diseases. 2-BBB’s lead product 2B3-101 (glutathione PEGylated liposomal doxorubicin) combines the G-Technology? with the existing chemotherapeutic agent doxorubicin for the possible treatment of brain metastases and glioma. It has completed a Phase I/IIa trial treating patients with various forms of brain cancer. 2-BBB’s second promising lead product is 2B3-102. 2B3-102 is a glutathione PEGylated liposomal methylprednisolone. It applies the anti-inflammatory glucocorticoid methylprednisolone to combat acute and chronic neuro-inflammation associated with several CNS indications including acute relapses of multiple sclerosis, optic neuritis, neuromyelitis optica and uveitis.2B3-201 has completed a Phase I clinical trial in healthy volunteers[77].

    2-BBB is a clear example of industry-driven research aiming at developing innovative passive targeting technologies to brain and brain metastases. They use triple passive targeting techniques to offer optimal safety and efficacy profiles, Glutathione passively targeting the cancerous intracellular reductive environment, PEGylation and liposomal vesicular carrier system[77].

    Nucleic acid

    RNA interference (RNAi) is an endogenous pathway for post-transcriptional silencing of gene expression that is triggered by double-stranded RNA, including endogenous microRNA (miRNA) and synthetic short interfering RNA[79]. MicroRNA-122 mediated RNAi brings new prospects[80]. Zhanget al.[81]miRNA-1258 in BMBC cells inhibited heparanase which regulates many molecules involved in angiogenesis and metastasis of the tumor.

    Advanced physically manipulated systems to disrupt BBB

    Another modality of addressing BBB passively is advanced physically manipulated systems that can be tightly mediated by stimuli to treat diseases specifically and with a controlled dosage of drugs. Physical manipulation can be achieved based on ultrasound, electricity, magnetism and photonic emission technologies[82]. Davaloset al.[83]applied pulsed electric fields into brain tissue of an animal, to cause temporary disruption of the BBB in a volume of brain tissue near the source of the pulsed electric fields over a specified time interval.

    The use of focused ultrasound (FUS) combined with circulating microbubbles is a non-invasive method that increases the permeability of BBTB and improves outcomes of trastuzumab; this technique was used by Parket al.[84]to improve outcomes with trastuzumab in a breast cancer brain metastasis model. Similarly,FUS in combination with microbubbles was able to temporarily disrupt the BBB enhancing the anti-tumor efficacy of the two anti-HER2 agents combination therapy[85]. Moreover, reversible disruption of the BBB by bursts of low frequency MRI-guided ultrasound enhances the brain delivery of monoclonal antibody -Herceptin (trastuzumab) in mice[86,87].

    Active targeting

    Active targeting was proposed for improved targeting efficacy[47]. These strategies consist in incorporating affinity molecules or taking advantage of influx transport systems expressed within the BBB/BBTB depending on specific interactions of ligand-receptor and antibody-antigen[47,88,89]. Also, several ligands have been studied and utilized to shuttle nanoparticles, antibodies, and drugs across the BBB and into the brain cells[90][Figure 1]. Supplementary Table 2 summarizes recent studies of actively targeted treatments for BCBM.

    Receptor-mediated transcytosis/ligand-based

    An overexpression of receptors or antigens in cancer acts as a potential target to achieve efficient drug uptake via receptor-mediated endocytosis[47]. Moreover, receptor-mediated transcytosis (RMT) allows for BBB transport of various macromolecules after initial binding of a targeting ligand to a receptor expressed on the brain endothelial cells[91]. Tumor-targeting ligands such as peptides and antibodies may effectively aid certain cytotoxic agents (either biological or synthetic) to deliver to the tumor cells, thereby improving therapeutic efficacy while limiting the exposure of normal tissues to the cytotoxic agents[92]. The transferrin receptor, the low-density lipoprotein receptor-related protein 1 (LRP-1), the insulin receptor and the nicotinic acetylcholine receptors are examples of receptor expression on the BBB.

    AngioChemTMInc. developed a series of aprotinin polypeptides (Angiopeps)[93]. Angiopep-2, a 19-aminoacid peptide, is one of the promising vectors designed to target the LRP-1 receptor, to mediate transcytosis across the BBB. It is derived from the human Kunitz domain[94]. Angiopep-2 can facilitate brain-targeted drug delivery through LRP-1-mediated transcytosis. Reginaet al.[95]demonstrated that a conjugate between angiopep-2 and an anti-HER2 mAb results in a new chemical entity, ANG4043. ANG4043 retainsin-vitrobinding affinity for the HER2 receptor and antiproliferative potency against BCBM rat model. This study showed increased uptake in brain endothelial cells and enhanced BBB permeability compared to poor brain penetration of anti-HER2 mAb alone. Similarly, Thomaset al.[96]showed that ANG1005 shows significantly improved delivery to brain and brain metastases of breast cancer compared to free paclitaxel in mice bearing BCBM.

    On the other hand, Orthmannet al.[97]formulated rigid and fluid liposomes entrapping Mitoxantrone and equipped with a 19-mer angiopeptide as a ligand. Angiopeptide bearing fluid liposomes showedin vitrothe highest cellular uptake and transcytosis. They were significantly better than the corresponding ligandfree fluid liposomes and ligand-bearing rigid vesicles however; the improvement was mainly depending on liposomal fluidity while the targeting contributed only to a minor degree. In 2016, Orthmannet al.[98]encapsulated oxaliplatin (OxP) in liposomes then bound angiopep-2 to the vesicular surface. They determined that the newly developed OxP liposomes significantly improved the treatment of subcutaneously and intracerebrally growing breast cancer, but the targeted angiopep-equipped liposomes showed no superior effectin vivo.

    Melanotransferrin (hMTf) is another target to the LRP-1 receptor, which was shown to deliver doxorubicin across BBB[99,100]. In order to overcome the trastuzumab inability to cross the BBB and treat brain metastases of HER2+ breast cancer, BT2111, a novel bioconjugate of trastuzumab was developed by BiOasis Inc.,on the hMTf (p97) TranscendTMvector platform[101]. This platform is an example of an actively targeted immunotherapy, aiding in enhancing the immunotherapy targetability, ability to cross the BB and clinical efficacy via the use of the targeting moiety hMTf.

    Another complex process involves binding to a primary, tumor-specific receptor activating endocytosis;using “Tumor-penetrating peptide”[102]. The prototypic peptide of this class, iRGD (CRGDKGPDC), contains the integrin-binding RGD motif[103]. The integrin-binding RGD sequence motif binds to αvβ3 and αvβ5 integrins, which are specifically expressed in tumor endothelial cells[102]. Hamiltonet al.[104]demonstrated that a single dose of iRGD had a significant effect on metastatic tumor progression and nonproliferative cancer cell retention when applied early in course of tumor development. Proteolytically processed iRGD also exerts anti-metastatic activity by binding to neuropilin-1 and activating an endocytic bulk transport pathway through tumor tissue. The iRGB platform offers an innovative dual targeting tool to target the tumor portion via the integrins and the RGB motif[103].

    Carrier-mediated transcytosis

    Naturally, carrier-mediated transcytosis (CMT) enables spontaneous internalization of small biomolecules[105,106]. CMT takes advantage of the immunological surveillance system of the brain, using circulating phagocytic cells such as monocytes or macrophages as Trojan horse to deliver drug molecules into the brain[107]. Such cells have a tendency to endocytose colloidal materials, for example, nano or microparticles, liposomes, and subsequent exocytosis to release drug and/or colloidal materials to external media[108]. Fidler and colleagues provided evidence that macrophages of blood monocyte origin can infiltrate experimental brain metastases while the BBB is intact.

    In 2012, Choiet al.[109]reported the first successful demonstration of the active delivery, using macrophages,of nanoparticles to brain metastases. Activated macrophages not only cross the BBB but they envelop the metastatic cells delivering the loaded nanoparticle to less than a cell width away from the nearest metastatic cell[109].

    CeII penetrating peptides

    Cell-penetrating peptides (CPP), that show great capacity in BBB transport, have the ability to transport protein or peptides into cells in a nonspecific, receptor-independent manner and non-immunogenic when compared with antibodies[110]. Considering their smaller size (up to 30 amino acids in length), cationic and/or amphipathic CPPs have a greater potential to penetrate the BBB than other transport systems. Short peptides, as targeted drug delivery vehicles, appear to have some advantages owing to their small size,efficient tissue penetrability, and minimal toxicity and immunogenicity.

    The first CPP, trans-activator of transcription (TAT), derived from human immunodeficiency virus-1, can be efficiently taken up from the surrounding media[111]. Morshedet al.[112]used PEGylated gold nanoparticle conjugated to TAT peptide as well as doxorubicin. This formulation offered extensive accumulation of particles throughout diffuse intracranial metastatic microsatellites. Moreover, it was shown to destabilize a brain capillary monolayer increasing its permeability. Fuet al.[113]combined brain metastatic breast carcinoma cell (231-BR)-binding peptide BRBP1, a cell penetrating peptide TAT, and a proapoptotic peptide KLA. The composite selectively homed to the tumors in vivo where it induced cellular apoptosis without significant toxicity on non-tumor tissues. Angiopep-mediated targeting also can be considered as one of the most promising ways to reach the CNS for the treatment of brain cancer or brain metastases[114].

    ConcIusion and future directions

    There is a global need for effective and safe pharmaceutical chemotherapeutic agents that have the potential to target tumors like BCBM.

    Conventional chemotherapy, radiation therapy and immunotherapy offers promising options for treating brain metastases, which is traditionally treated with surgery.

    In 2005, the chemotherapy temozolomide (Temodar?) was approved to treat glioblastoma (GBM) patients.However, over 50% of GBM tumors generate a DNA repair protein (methylguanine methyltransferase)that effectively combats and neutralizes temozolomide chemotherapy. There are two FDA approved immunotherapies for brain and nervous system cancers and metastases. Bevacizumab (Avastin?) and Dinutuximab (Unituxin?). Several other immunotherapies are being used to treat different types of brain cancers in clinical trials. However, there are no FDA-approved systemic treatments specific to BCBM to date[41]. Improved insights into the microenvironment and metastatic cascade processes have resulted in the development of several novel chemotherapeutic and immunotherapeutic drugs and strategies[35,36,38,39,54]. Such novel chemotherapeutic and immunotherapeutic strategies adopt active and passive targeting strategies to enhance the clinical treatment effects.

    Surveying the published research papers and patents also revealed a major drawback in the methodology design, which is the lack of standardization of efficacy and safety profiles. Various sophisticated nanosystems and conjugates have been studied to either actively or passively target BCBM. However, most of these complex delivery systems fail to reach the market due to high cost, instability and difficulty of scaling up. In addition, majority of the reagents used in the formulation of such novel therapeutic systems to improve the stability; are not included in the FDA approved inactive ingredient database. The main question of this review is to query the preferential advantage of either active or passive targeting in combating brain metastases of breast cancer. Such question is a major ongoing debate as revealed by the recent patents and papers portfolio.

    Passive targeting could be a cheaper, long-term effective and safe technique to target tumor cells without triggering resistance for active targeting moieties. Numerous significant downsides in active tumor-targeted drug delivery were identified[115-120]. Interestingly, passive targeting can be tailored and designed via simple ideologies and techniques such as simple PEGylation, size modifications or even shape customization. It was shown that slender shape and particles modifications such as drifting from the conventional spherical particulate structures, can yield high effectual passive targeting[121].

    Active targeting shows significant results in combating cancer initially with long-term degraded efficacy profile, most potentially attributed to multidrug resistance[119]. Additionally, the marginally augmented efficacy of active targeting strategies does not substantiate the extremely higher cost, difficulty in clinical application and the high complexity level of the carrier system[54,78,115-120,122,123]. Interestingly, passive targeting can be tailored and designed via simple ideologies and techniques such as simple PEGylation, size modifications or even shape customization.

    Multiple researchers suggested the preferential long-term advantage of passive targeting over active targeting such as Lammerset al.[122]and Rosenblumet al.[123]. Such researches highlighted the need for future realistic and scalable efforts to address some of the conceptual drawbacks of drug targeting to tumors such as resistance, and that strategies should be developed to overcome these deficiencies. Such research presented evidence that passive targeting yield very comparable results to active targeting on the short term and superior results on the long term[54,78,115-120,122,123].

    Some of the main drawbacks of engineered nanotechnologies, either active or passive, are the poor robust and cost-effective toolbox to characterize nanomaterials and to quantify exposure in test systems (dosimetry),lack of standard techniques and methods for test, hazard, and risk assessment strategies and lack of specific safety assessment strategies in evaluating nanotoxicities. However, passive targeting offers less problematic strategy compared to active targeting engineered nanotechnologies in terms of nano-safety and its quantitative characterization[124].

    Passive targeting could provide an applied direction for the advance of novel management tackles and therapeutics for brain metastases of breast cancer for researchers worldwide, paving the road to affordable,scalable, stable, efficient and safe management strategies. Such observations were evident from the multiple passive targeting products under Phase II and Phase III clinical trials from multiple pharmaceutical firms such as Nektar Therapeutics, BiOasis Inc. and 2-BBB. Such companies have invested heavily into the development of new formulations that combat brain barriers, targeting the brain and accumulates in tumor tissue rather than normal cells, to enhance the nano-safety profiles to chemotherapeutics. This may not be only attributed to their need to expand their portfolio to increase their commercial value for possible products buyouts and licensing by big pharmaceutical firms, but the safety and efficacy potential of such passively targeted nanotherapeutics in the treatment strategies of brain metastases of breast cancer compared to current conventional modalities and research-driven active-targeting initiatives.

    Such conclusions have driven the industry to invest heavily on passive targeting compared to active targeting. A major focus by industry is the successful transformation of such novel technologies from bench to bedside with reasonable cost, scale-up abilities and formulation robustness and reproducibility, which are achievable via passive targeting technologies compared to active targeting. Active targeting ligand post-insertion and labeling techniques need to be extensively researched for ease of application for active targeting to gain industrial momentum. Conclusively, patents and products under development should focus on simple passively targeted bioconjugate structures, which are easily synthesized with high yield, reduced cost and high stability profile of the final formulation.

    DECLARATIONS

    Authors’ contributions

    Manuscript writing: Kamal NH, El-Amrawy F, Ali HA, Nounou MI

    Manuscript proofing and revisions: Edafiogho I, Nounou MI

    Design: Nounou MI

    AvaiIabiIity of data and materiaIs

    Not applicable.

    FinanciaI support and sponsorship

    None.

    ConfIicts of interest

    All authors declared that there are no conflicts of interest.

    EthicaI approvaI and consent to participate

    Not applicable.

    Consent for pubIication

    Not applicable.

    Copyright

    ? The Author(s) 2019.

    中文字幕制服av| 日本与韩国留学比较| 三级国产精品欧美在线观看| 国产有黄有色有爽视频| 日本黄色日本黄色录像| 伊人久久精品亚洲午夜| 少妇高潮的动态图| 伦理电影大哥的女人| 日韩,欧美,国产一区二区三区| 日韩电影二区| 国产免费又黄又爽又色| 秋霞伦理黄片| 久久毛片免费看一区二区三区| 中国美白少妇内射xxxbb| 少妇的逼水好多| 午夜免费男女啪啪视频观看| 蜜桃在线观看..| 日韩欧美一区视频在线观看 | 成人美女网站在线观看视频| 一级毛片aaaaaa免费看小| 夜夜爽夜夜爽视频| av卡一久久| 男女边吃奶边做爰视频| 狂野欧美激情性xxxx在线观看| 精品久久国产蜜桃| 日韩大片免费观看网站| 国产一区亚洲一区在线观看| 国产精品人妻久久久影院| 精品一区二区免费观看| 亚洲美女视频黄频| 日韩制服骚丝袜av| 亚洲国产精品专区欧美| 最近最新中文字幕免费大全7| 少妇被粗大猛烈的视频| 视频区图区小说| 亚洲美女视频黄频| 爱豆传媒免费全集在线观看| 国产欧美另类精品又又久久亚洲欧美| 国产精品人妻久久久影院| 极品人妻少妇av视频| 熟女电影av网| 国产精品.久久久| 国产伦理片在线播放av一区| 如何舔出高潮| 亚洲欧美日韩另类电影网站| 亚洲,一卡二卡三卡| 精品国产国语对白av| 久久6这里有精品| 午夜免费鲁丝| 六月丁香七月| 国产免费视频播放在线视频| 久久午夜福利片| 99九九在线精品视频 | 国产精品人妻久久久久久| 麻豆成人av视频| 精品人妻熟女毛片av久久网站| 人妻制服诱惑在线中文字幕| 欧美日本中文国产一区发布| av天堂中文字幕网| 欧美三级亚洲精品| 亚洲精品久久久久久婷婷小说| 日产精品乱码卡一卡2卡三| 黄片无遮挡物在线观看| 精品国产乱码久久久久久小说| 亚洲av男天堂| 在线观看三级黄色| √禁漫天堂资源中文www| 91久久精品国产一区二区三区| 男女边吃奶边做爰视频| 天堂8中文在线网| 久久精品久久精品一区二区三区| 在线观看美女被高潮喷水网站| 国产精品女同一区二区软件| 一二三四中文在线观看免费高清| 午夜91福利影院| 五月天丁香电影| 国产精品99久久99久久久不卡 | 日韩制服骚丝袜av| 亚洲欧美精品专区久久| 韩国av在线不卡| 91精品国产九色| 新久久久久国产一级毛片| 国产老妇伦熟女老妇高清| 伦理电影免费视频| 久久久久视频综合| 午夜激情久久久久久久| 18禁裸乳无遮挡动漫免费视频| 一边亲一边摸免费视频| 自拍欧美九色日韩亚洲蝌蚪91 | 极品教师在线视频| 免费黄网站久久成人精品| 老女人水多毛片| 老女人水多毛片| 久久婷婷青草| 亚洲欧美成人精品一区二区| 不卡视频在线观看欧美| 国产精品久久久久久久电影| 汤姆久久久久久久影院中文字幕| 欧美日韩在线观看h| 亚洲怡红院男人天堂| 亚州av有码| a级毛片免费高清观看在线播放| 国模一区二区三区四区视频| 乱系列少妇在线播放| 国产欧美日韩一区二区三区在线 | 老司机亚洲免费影院| 国产淫片久久久久久久久| 国产精品99久久99久久久不卡 | 成人18禁高潮啪啪吃奶动态图 | 色吧在线观看| 777米奇影视久久| 久久久久久伊人网av| 国产一区亚洲一区在线观看| 国国产精品蜜臀av免费| 国产亚洲最大av| 毛片一级片免费看久久久久| 麻豆成人午夜福利视频| 18禁动态无遮挡网站| 国产精品伦人一区二区| 国产爽快片一区二区三区| 精品一区二区三卡| 亚洲性久久影院| 精品熟女少妇av免费看| 国产午夜精品久久久久久一区二区三区| 美女主播在线视频| 国产国拍精品亚洲av在线观看| 在线观看国产h片| 亚洲婷婷狠狠爱综合网| 久久精品夜色国产| 三上悠亚av全集在线观看 | 自拍偷自拍亚洲精品老妇| 日韩大片免费观看网站| 国产免费视频播放在线视频| 成年人午夜在线观看视频| 色视频www国产| av在线app专区| 国产探花极品一区二区| 男的添女的下面高潮视频| 国产极品粉嫩免费观看在线 | 久久女婷五月综合色啪小说| 在线观看av片永久免费下载| 国产黄频视频在线观看| 一区二区av电影网| 青春草亚洲视频在线观看| 丰满少妇做爰视频| 亚洲国产成人一精品久久久| 国产色婷婷99| 精品国产露脸久久av麻豆| 只有这里有精品99| 五月玫瑰六月丁香| 91在线精品国自产拍蜜月| 国产精品嫩草影院av在线观看| 国产中年淑女户外野战色| 丝瓜视频免费看黄片| 97超碰精品成人国产| 高清午夜精品一区二区三区| 91久久精品电影网| 又大又黄又爽视频免费| 男女边吃奶边做爰视频| 王馨瑶露胸无遮挡在线观看| 一级黄片播放器| 又黄又爽又刺激的免费视频.| 黄色一级大片看看| 亚洲av中文av极速乱| 久久久久久伊人网av| 免费大片18禁| 国产成人aa在线观看| 99热这里只有是精品50| 欧美人与善性xxx| 22中文网久久字幕| 免费观看a级毛片全部| 中国国产av一级| 亚洲精品国产av成人精品| 熟妇人妻不卡中文字幕| a级片在线免费高清观看视频| 你懂的网址亚洲精品在线观看| 日本与韩国留学比较| 国产亚洲午夜精品一区二区久久| 国产免费一区二区三区四区乱码| 欧美日韩亚洲高清精品| 青春草视频在线免费观看| av天堂中文字幕网| 一区在线观看完整版| 有码 亚洲区| 一本大道久久a久久精品| 亚洲精品一区蜜桃| 国产成人午夜福利电影在线观看| 久久久久久久久久人人人人人人| 日韩av在线免费看完整版不卡| 美女国产视频在线观看| 在线观看免费高清a一片| 国产视频内射| av专区在线播放| 午夜福利在线观看免费完整高清在| 亚洲美女视频黄频| 国产精品三级大全| 色婷婷久久久亚洲欧美| 久久久久国产精品人妻一区二区| 精品亚洲乱码少妇综合久久| 一个人看视频在线观看www免费| 久久99精品国语久久久| 免费av中文字幕在线| 在现免费观看毛片| 久久久a久久爽久久v久久| 亚洲经典国产精华液单| 少妇人妻一区二区三区视频| 中国国产av一级| 国产中年淑女户外野战色| 久久精品熟女亚洲av麻豆精品| 免费观看av网站的网址| 九九久久精品国产亚洲av麻豆| 高清不卡的av网站| 91精品国产九色| 色5月婷婷丁香| a级毛片在线看网站| 少妇的逼好多水| 在线观看美女被高潮喷水网站| 国产中年淑女户外野战色| 两个人免费观看高清视频 | 综合色丁香网| 波野结衣二区三区在线| 22中文网久久字幕| 午夜激情久久久久久久| 免费观看的影片在线观看| videos熟女内射| 免费看光身美女| 国产精品成人在线| 一级片'在线观看视频| 精品卡一卡二卡四卡免费| 亚洲精品中文字幕在线视频 | 精品人妻偷拍中文字幕| 日韩中文字幕视频在线看片| 午夜老司机福利剧场| 成年av动漫网址| 免费看光身美女| 精品久久久久久久久亚洲| 久久综合国产亚洲精品| 国产日韩欧美视频二区| h视频一区二区三区| 成人毛片60女人毛片免费| 一边亲一边摸免费视频| 男人爽女人下面视频在线观看| 国产高清三级在线| 人体艺术视频欧美日本| 亚洲伊人久久精品综合| 国模一区二区三区四区视频| 丝瓜视频免费看黄片| 久久女婷五月综合色啪小说| 搡女人真爽免费视频火全软件| 男男h啪啪无遮挡| 免费黄网站久久成人精品| av福利片在线观看| 免费观看a级毛片全部| 亚洲国产精品一区三区| 97精品久久久久久久久久精品| 日韩一区二区视频免费看| 国产免费一级a男人的天堂| 日韩中文字幕视频在线看片| 99久久精品国产国产毛片| 国产精品麻豆人妻色哟哟久久| 天堂中文最新版在线下载| 精品一区二区免费观看| 精品少妇内射三级| 国产日韩欧美亚洲二区| 国产精品一区二区性色av| 亚洲精品国产成人久久av| 日本黄色片子视频| 日本欧美视频一区| 久久久久国产精品人妻一区二区| 日韩欧美一区视频在线观看 | 丰满迷人的少妇在线观看| 国产在线一区二区三区精| 伊人亚洲综合成人网| 国产精品久久久久久av不卡| 成年女人在线观看亚洲视频| 五月伊人婷婷丁香| 国模一区二区三区四区视频| 亚洲三级黄色毛片| 少妇人妻一区二区三区视频| 女性被躁到高潮视频| 一个人看视频在线观看www免费| xxx大片免费视频| a级毛色黄片| 精品酒店卫生间| 亚洲精品国产成人久久av| 日日啪夜夜爽| 国产午夜精品久久久久久一区二区三区| 99久国产av精品国产电影| 不卡视频在线观看欧美| 又大又黄又爽视频免费| 成年人午夜在线观看视频| 久久av网站| 七月丁香在线播放| 国产亚洲一区二区精品| 国产白丝娇喘喷水9色精品| 亚洲av男天堂| 在线观看www视频免费| 夜夜看夜夜爽夜夜摸| 人人妻人人添人人爽欧美一区卜| 亚洲图色成人| 成人毛片60女人毛片免费| 日本av手机在线免费观看| 日本91视频免费播放| 日韩欧美 国产精品| 久久韩国三级中文字幕| 免费看不卡的av| 国产伦精品一区二区三区视频9| 午夜激情福利司机影院| 女性生殖器流出的白浆| 日本猛色少妇xxxxx猛交久久| 99热这里只有是精品在线观看| 夜夜看夜夜爽夜夜摸| 一级片'在线观看视频| 热re99久久精品国产66热6| 熟女电影av网| 校园人妻丝袜中文字幕| tube8黄色片| 交换朋友夫妻互换小说| 欧美日韩国产mv在线观看视频| 欧美老熟妇乱子伦牲交| 亚洲av福利一区| 久久久久久人妻| 久久热精品热| 久久青草综合色| 亚洲国产精品国产精品| 亚洲欧美一区二区三区黑人 | 不卡视频在线观看欧美| 亚洲av福利一区| 五月天丁香电影| 少妇被粗大的猛进出69影院 | 中文精品一卡2卡3卡4更新| 另类精品久久| 在线看a的网站| 精品少妇久久久久久888优播| 极品少妇高潮喷水抽搐| 高清午夜精品一区二区三区| 一级毛片 在线播放| 成人无遮挡网站| 国产深夜福利视频在线观看| 欧美激情极品国产一区二区三区 | 伊人久久国产一区二区| 久久99精品国语久久久| 久久国内精品自在自线图片| 另类亚洲欧美激情| 国产精品偷伦视频观看了| 人人妻人人添人人爽欧美一区卜| 丝袜在线中文字幕| 欧美精品人与动牲交sv欧美| 一区二区三区免费毛片| 欧美精品高潮呻吟av久久| 在线观看免费日韩欧美大片 | 婷婷色av中文字幕| 国产午夜精品一二区理论片| 2022亚洲国产成人精品| 亚洲欧洲精品一区二区精品久久久 | av一本久久久久| 黄色视频在线播放观看不卡| 国产欧美日韩精品一区二区| 纵有疾风起免费观看全集完整版| 又粗又硬又长又爽又黄的视频| 青春草国产在线视频| 人人妻人人看人人澡| 亚洲精品日韩在线中文字幕| 欧美少妇被猛烈插入视频| 熟女人妻精品中文字幕| 人妻 亚洲 视频| 久久久午夜欧美精品| 色视频在线一区二区三区| 国产精品麻豆人妻色哟哟久久| 国产精品福利在线免费观看| 最近手机中文字幕大全| 欧美+日韩+精品| 爱豆传媒免费全集在线观看| 亚洲精品中文字幕在线视频 | 最近最新中文字幕免费大全7| 中文乱码字字幕精品一区二区三区| 大香蕉久久网| 国产精品免费大片| 老熟女久久久| 日日啪夜夜撸| 成人无遮挡网站| 亚洲性久久影院| 国产亚洲91精品色在线| 99热这里只有精品一区| 天天躁夜夜躁狠狠久久av| 在线观看免费高清a一片| 午夜视频国产福利| 亚洲国产精品专区欧美| 建设人人有责人人尽责人人享有的| 亚洲电影在线观看av| 久久久久久久精品精品| 欧美一级a爱片免费观看看| 国产亚洲5aaaaa淫片| 我要看黄色一级片免费的| 不卡视频在线观看欧美| 免费不卡的大黄色大毛片视频在线观看| 久久精品夜色国产| 欧美高清成人免费视频www| 黄色日韩在线| 久久久久久伊人网av| 亚洲国产最新在线播放| a级一级毛片免费在线观看| 99精国产麻豆久久婷婷| 国产一区二区在线观看av| 国语对白做爰xxxⅹ性视频网站| 乱人伦中国视频| 我的老师免费观看完整版| 一级二级三级毛片免费看| 久热久热在线精品观看| 成年美女黄网站色视频大全免费 | 亚洲内射少妇av| 色视频www国产| 亚洲成色77777| 在线观看三级黄色| 亚洲精品第二区| 一个人看视频在线观看www免费| 又大又黄又爽视频免费| 高清欧美精品videossex| 高清视频免费观看一区二区| 看非洲黑人一级黄片| av女优亚洲男人天堂| 久久鲁丝午夜福利片| 男女边吃奶边做爰视频| 女的被弄到高潮叫床怎么办| 亚洲在久久综合| 精品国产乱码久久久久久小说| 丰满少妇做爰视频| 亚洲丝袜综合中文字幕| 黄片无遮挡物在线观看| 18禁在线无遮挡免费观看视频| 午夜影院在线不卡| 男人舔奶头视频| 亚洲,一卡二卡三卡| 久久狼人影院| 国内揄拍国产精品人妻在线| 亚洲精品第二区| 成人亚洲欧美一区二区av| 欧美另类一区| 国产精品久久久久久久久免| 国产av精品麻豆| 夫妻午夜视频| 男人狂女人下面高潮的视频| av天堂中文字幕网| 国产精品三级大全| 国产无遮挡羞羞视频在线观看| av天堂中文字幕网| 男女边吃奶边做爰视频| av在线app专区| av在线观看视频网站免费| 欧美精品一区二区免费开放| av福利片在线| 国产片特级美女逼逼视频| 97超碰精品成人国产| 日韩伦理黄色片| 国产精品熟女久久久久浪| 亚洲欧美成人精品一区二区| 又大又黄又爽视频免费| 熟女人妻精品中文字幕| 日本黄色日本黄色录像| 七月丁香在线播放| 韩国av在线不卡| 国产白丝娇喘喷水9色精品| 日韩av免费高清视频| 国产精品久久久久久久久免| 夜夜看夜夜爽夜夜摸| 人人澡人人妻人| 涩涩av久久男人的天堂| 在线观看免费日韩欧美大片 | 色婷婷av一区二区三区视频| a 毛片基地| 女性生殖器流出的白浆| 九色成人免费人妻av| 欧美成人精品欧美一级黄| 永久网站在线| 亚洲精品久久午夜乱码| 中文字幕久久专区| 亚洲av男天堂| av国产久精品久网站免费入址| 十八禁高潮呻吟视频 | 99久久中文字幕三级久久日本| 久久韩国三级中文字幕| 高清在线视频一区二区三区| 最近中文字幕2019免费版| 一本色道久久久久久精品综合| 中文字幕av电影在线播放| 国产亚洲一区二区精品| 亚洲精品一二三| 亚洲av中文av极速乱| av一本久久久久| 熟女人妻精品中文字幕| 日韩精品免费视频一区二区三区 | 国产免费又黄又爽又色| 大陆偷拍与自拍| 亚洲国产精品专区欧美| 国模一区二区三区四区视频| 亚洲第一av免费看| av免费观看日本| 国产成人aa在线观看| 国产av精品麻豆| 视频中文字幕在线观看| 日本欧美视频一区| 日韩精品有码人妻一区| 亚洲精品国产av蜜桃| 成年人免费黄色播放视频 | 久久久久久人妻| 国产精品国产三级国产av玫瑰| 一级爰片在线观看| 又粗又硬又长又爽又黄的视频| 国产在线男女| 欧美国产精品一级二级三级 | 久久影院123| 伦精品一区二区三区| 国产黄片视频在线免费观看| 大香蕉久久网| 视频中文字幕在线观看| 少妇被粗大的猛进出69影院 | 十八禁高潮呻吟视频 | 亚洲美女搞黄在线观看| 91aial.com中文字幕在线观看| 国产淫片久久久久久久久| 久久精品国产亚洲av涩爱| 午夜久久久在线观看| 久久久国产欧美日韩av| 欧美bdsm另类| 在线观看www视频免费| 久久久亚洲精品成人影院| 午夜福利影视在线免费观看| 欧美日本中文国产一区发布| 久久人人爽人人爽人人片va| 老熟女久久久| av免费观看日本| 丰满饥渴人妻一区二区三| 日本黄大片高清| 黄色毛片三级朝国网站 | 免费不卡的大黄色大毛片视频在线观看| 国产无遮挡羞羞视频在线观看| 最新的欧美精品一区二区| 超碰97精品在线观看| 少妇人妻一区二区三区视频| 在线免费观看不下载黄p国产| 精品熟女少妇av免费看| 最后的刺客免费高清国语| 不卡视频在线观看欧美| 偷拍熟女少妇极品色| 国产色婷婷99| 桃花免费在线播放| 亚洲图色成人| 观看av在线不卡| 少妇人妻精品综合一区二区| 永久网站在线| 春色校园在线视频观看| 国产白丝娇喘喷水9色精品| 啦啦啦中文免费视频观看日本| 在线播放无遮挡| 欧美另类一区| 精品一区二区三卡| 爱豆传媒免费全集在线观看| 乱人伦中国视频| 26uuu在线亚洲综合色| 美女视频免费永久观看网站| 国产 一区精品| 国产视频内射| 美女大奶头黄色视频| 国产成人aa在线观看| 男女免费视频国产| 插阴视频在线观看视频| 黄色日韩在线| 久久久久网色| 亚洲精品,欧美精品| 中文字幕免费在线视频6| 97超视频在线观看视频| 80岁老熟妇乱子伦牲交| 天堂8中文在线网| 成年人免费黄色播放视频 | 在线观看人妻少妇| 一级a做视频免费观看| 亚洲无线观看免费| 高清不卡的av网站| 日韩熟女老妇一区二区性免费视频| 一级毛片我不卡| 边亲边吃奶的免费视频| 少妇熟女欧美另类| 国产精品无大码| 久久久久久久久久久丰满| 一边亲一边摸免费视频| 18+在线观看网站| 亚洲国产精品一区三区| 国产精品99久久久久久久久| av天堂久久9| 亚洲精品一二三| av天堂久久9| 欧美高清成人免费视频www| 91久久精品国产一区二区三区| 精品一品国产午夜福利视频| 精品久久久久久久久av| 午夜免费观看性视频| 一级毛片电影观看| 国产免费又黄又爽又色| 午夜久久久在线观看| 久久精品熟女亚洲av麻豆精品| 精品午夜福利在线看| 成人综合一区亚洲| 少妇的逼好多水| 久热这里只有精品99| 男女边吃奶边做爰视频| 日韩一区二区视频免费看| 夫妻午夜视频| 午夜视频国产福利| 我要看日韩黄色一级片| 高清视频免费观看一区二区| 久久人人爽av亚洲精品天堂| 在线精品无人区一区二区三| 偷拍熟女少妇极品色| 99国产精品免费福利视频| av在线播放精品|